Bifi dobacteria are common inhabitants of human gut and play a signifi cant role in establishing a well-balanced intestinal microbiota. The strain Bifi dobacterium longum CECT 7347 (ES1) has been demonstrated to ameliorate damage caused by gluten in celiac disease (CD), both In vitro and in a murine model. Studies suggest that administering this B. longum strain to supplement the gluten-free diet could provide an additional strategy, thereby improving the health status of patients. Here, we report an in-depth study of this strain, adopting a multidisciplinary strategy to demonstrate its safety according to FAO/WHO criteria for probiotic selection. Whole genome sequencing using a massive sequencing approach on the 454 platforms and annotation showed neither relevant virulence nor potential antibiotic resistance genes.
Citation: Chenoll E, Codoñer FM, Silva A, Ibáñez A, Martinez-Blanch JF, et al. (2013) Genomic Sequence and Pre-Clinical Safety Assessment of Bifi dobacterium longum CECT 7347, a Probiotic able to Reduce the Toxicity and Infl ammatory Potential of Gliadin-Derived Peptides. J Prob Health 1:106. doi: 10.4172/2329-8901.1000106